Overview
- Mirum will pay $250 million in cash and $370 million in stock upfront, with up to $200 million in sales-based milestones, securing worldwide rights to brelovitug.
- The company raised $200 million in a private placement to support development and potential commercialization of the program.
- Brelovitug is in a Phase 3 study for chronic hepatitis D, a severe infection with no approved therapies, with topline results expected in the second half of 2026 and a potential 2027 U.S. launch if successful.
- In mid-stage testing, the antibody reduced hepatitis D virus levels in all patients at 48 weeks and up to 82% achieved liver enzyme normalization, according to company reports.
- The acquisition is expected to close in the first quarter of 2026, and Mirum will evaluate Bluejay’s remaining pipeline, including a preclinical MASH candidate.